{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["De Maria R"],"funding":["FPRC 5 per mille 2020 MUR","IRCC"],"pagination":["306"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12433426"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["74(10)"],"pubmed_abstract":["Advanced-stage sarcomas pose a major challenge in oncology, as they are often resistant to conventional therapies and associated with poor prognosis. CAR-based cellular immunotherapy is emerging as a very promising therapeutic option; however, clinically relevant animal models are urgently needed to accelerate the clinical development of these approaches. B7-H3 molecule, due to its low expression in normal tissue, high prevalence in multiple human cancers, and association with cancer stemness and aggressiveness, represents one of the most attractive targets for CAR-immunotherapy. In this study, we established a preclinical cellular immunotherapy platform based on canine cytokine-induced killer cells (CIK) redirected by an antihuman B7-H3 CAR against canine sarcoma cells and 3D sarcoma sphe"],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation."],"pmcid":["PMC12433426"],"funding_grant_id":["Ricerca Corrente 2024","K9 HUMAN PROGRAM."],"pubmed_authors":["Landoni E","Aresu L","Capellero S","Vitali L","Sangiolo D","Berrino E","Leuci V","Grignani G","De Maria R","Vigna E","Dotti G","Sapino A","Olimpo M","Proment A","Donini C","Accornero P","Cesar Conti L","Massa A","Galvagno F"],"additional_accession":[]},"is_claimable":false,"name":"Development and activity of canine B7-H3-CAR.CIK lymphocytes against sarcomas: preclinical evidence and perspectives for human clinical translation.","description":"Advanced-stage sarcomas pose a major challenge in oncology, as they are often resistant to conventional therapies and associated with poor prognosis. CAR-based cellular immunotherapy is emerging as a very promising therapeutic option; however, clinically relevant animal models are urgently needed to accelerate the clinical development of these approaches. B7-H3 molecule, due to its low expression in normal tissue, high prevalence in multiple human cancers, and association with cancer stemness and aggressiveness, represents one of the most attractive targets for CAR-immunotherapy. In this study, we established a preclinical cellular immunotherapy platform based on canine cytokine-induced killer cells (CIK) redirected by an antihuman B7-H3 CAR against canine sarcoma cells and 3D sarcoma sphe","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-06-01T14:02:02.707Z","creation":"2026-04-08T13:19:03.718Z"},"accession":"S-EPMC12433426","cross_references":{"pubmed":["40944715"],"doi":["10.1007/s00262-025-04163-4"]}}